Sepsis News and Research

Latest Sepsis News and Research

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.

16 Mar 2010

Cheetah Medical closes $20M financing round; plans to expand hemodynamic monitoring market

Cheetah Medical, a worldwide leader in noninvasive hemodynamic and cardiac output monitoring technology, announced today the closing of a $20 million financing round. The financing was led by Ascension Health Ventures (AHV) and also included Robert Bosch Venture Capital (RBVC), MVM Life Science Partners (MVM) and existing investors.

16 Mar 2010

Study shows experimental thyroid drug reduces cholesterol

An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine. An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research tested a substance called Eprotirome in patients with high cholesterol.

12 Mar 2010

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

12 Mar 2010

A new way to control blood pressure

The control of blood pressure is central to people's wellbeing. One in three Australians suffer from high blood pressure (hypertension), a condition which can lead to coronary heart disease, heart failure, stroke and kidney failure.

11 Mar 2010

Inadvertent exposure of hospital housekeepers to drug-resistant "Superbugs" may lead to hospital-infection epidemic

One cause of the rampant international hospital-infection epidemic may be the "inadvertent exposure" of hospital housekeepers and transporters to antibiotic-resistant "Superbugs" such as MRSA, says TeleTracking Technologies CEO Anthony Sanzo.

10 Mar 2010

NIH awards Phase I SBIR grant to DNA Medicine Institute for emergency blood sensor

The DNA Medicine Institute, a commercial organization focused on advancing human health through innovation, today announced that it has been awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

9 Mar 2010

Abt Associates receives two new contracts to evaluate effectiveness of H1N1 vaccine

The Centers for Disease Control and Prevention has awarded Abt Associates two new contracts to evaluate the effectiveness of the H1N1 vaccine among health care workers and children under the age of 18.

6 Mar 2010

Postoperative complications more likely to occur at low-volume institutions

The frequency of post-operative complications following surgery for liver cancer is associated with a hospital having a low volume of liver surgery. Investigators at The Cancer Institute of New Jersey (CINJ) are presenting that finding at the 63rd Annual Society of Surgical Oncology Symposium taking place this week in St. Louis. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Mar 2010

Recent releases in Global Health

The WHO's March Bulletin is a special themed issue focusing on communicable diseases in Southeast Asia. The publication addresses tuberculosis, cholera, neglected tropical diseases and family planning in the region (March 2010).

6 Mar 2010

Shock: Norepinephrine favored over dopamine

Physicians treating patients with shock should consider norepinephrine instead of dopamine as a tool for stabilizing blood pressure, according to an editorial in the March 4, 2010, issue of the New England Journal of Medicine (NEJM).

3 Mar 2010

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

BioMS Medical Corp. today reported that Spectral Diagnostics has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxin(TM), a therapeutic hemoperfusion device for the treatment of severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxin(TM) in the United States.

3 Mar 2010

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Stem Cell Innovations announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.

3 Mar 2010

Study: Patients with community-acquired pneumonia who develop AKI more likely to die after discharge

Patients hospitalized with even mild to moderate community-acquired pneumonia who develop acute kidney injury (AKI) are more likely to die after discharge than pneumonia patients whose kidneys remain healthy, according to a University of Pittsburgh School of Medicine study in the February issue of Kidney International.

3 Mar 2010

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

Spectral Diagnostics Inc., a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing the Company to conduct a pivotal trial in the United States.

2 Mar 2010

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S. Rare Disease Day observance on February 28.

1 Mar 2010

HealthGrades America’s 50 Best Hospitals for 2010 identified

The HealthGrades America’s 50 Best Hospitals for 2010 were identified in a report issued today by the leading independent healthcare ratings organization. The analysis, which examined objective patient outcomes over three years at all 5,000 of the nation’s nonfederal hospitals, found that the 50 Best Hospitals had mortality rates that were, on average, 27% lower than other hospitals.

25 Feb 2010

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine.

25 Feb 2010

Comparison study of two treatment strategies for severe sepsis reveals similar short-term survival rates

A comparison of two strategies for treating severe sepsis or septic shock finds that using lactate levels measured in blood samples showed a similar short-term survival rate compared to a treatment regimen using central venous oxygen saturation measured using a specialized catheter, according to a study in the February 24 issue of JAMA.

24 Feb 2010

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Good Samaritan Hospital in Los Angeles is named as One of America’s 50 Best Hospitals in 2010 by HealthGrades, Inc., the nation’s leading independent healthcare ratings organization.

24 Feb 2010

Sepsis News and Research

Latest Sepsis News and Research

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cheetah Medical closes $20M financing round; plans to expand hemodynamic monitoring market

Study shows experimental thyroid drug reduces cholesterol

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

A new way to control blood pressure

Inadvertent exposure of hospital housekeepers to drug-resistant "Superbugs" may lead to hospital-infection epidemic

NIH awards Phase I SBIR grant to DNA Medicine Institute for emergency blood sensor

Abt Associates receives two new contracts to evaluate effectiveness of H1N1 vaccine

Postoperative complications more likely to occur at low-volume institutions

Recent releases in Global Health

Shock: Norepinephrine favored over dopamine

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Study: Patients with community-acquired pneumonia who develop AKI more likely to die after discharge

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

HealthGrades America’s 50 Best Hospitals for 2010 identified

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Comparison study of two treatment strategies for severe sepsis reveals similar short-term survival rates

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Sepsis News and Research

Latest Sepsis News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in